Boeing will take a nearly $5 billion charge in the second quarter to compensate 737 Max customers as the planes remain grounded.Airlinesread more
Earlier, Williams delivered a speech at the annual meeting of the Central Bank Research Association in which he said, "It's better to take preventative measures than to wait...The Fedread more
Microsoft beat on top and bottom lines, and guidance was just ahead of expectations, but the company's Azure growth is slowing down.Technologyread more
"We've seen Netflix stumble before, especially maybe after a price hike, but not quite like this," Jim Cramer says.Mad Money with Jim Cramerread more
Trump said the USS Boxer destroyed Iran's drone in the Strait of Hormuz on Thursday in a "defensive action."Politicsread more
They also voted to absolve themselves, their party and the voters who elected them – like the ones Trump inspired to chant "send her back" at a rally Wednesday in North...Politicsread more
See which stocks are posting big moves after the bell on July 18.Market Insiderread more
House Democrats contend the $15 per hour minimum wage bill will lift workers who have not seen the benefits of a strong economy.Politicsread more
The Philadelphia Fed saw its primary gauge measuring the sector jump from 0.3 in June to 21.8, far better than Wall Street estimates of 5 and the highest in a year.Economyread more
"It's better to take preventative measures than to wait for disaster to unfold," Williams told the annual meeting of the Central Bank Research Association.The Fedread more
CrowdStrike reports first earnings report since IPO.Technologyread more
Mylan has come under fire over the $600 price tag on its EpiPen, and the controversy has extended to pharmacy benefits managers like Express Scripts. Shares of Express Scripts dropped 6 percent Thursday.
Earlier in the day, Bresch discussed the repeated big price hikes, telling CNBC that intermediaries including wholesalers, retailers and pharmacy benefit managers add to the ultimate cost.
However, Express Scripts' Dr. Steve Miller said his company would love to see lower drug prices.
"If she wants to lower the price she can lower the price today," Miller said in a later interview with CNBC's "Closing Bell. "
"We'd pass the savings that we take from the marketplace back to our plans."
While there have also been calls for overall transparency on drug pricing, Miller said the one area there should not be transparency is with his competitors. That way, a price war can be created that can drive down prices.
"Mylan has a monopoly and we've seen this time and time again. Because when companies have a monopoly for that temporary part of time, we actually can't have the free market work. We can't pit competition against each other and drive down the price, and she's capitalizing on it," he said.
Miller pointed out that in the last 18 months, Express Scripts' copays for EpiPens have risen less than 50 cents, from $73.03 to $73.50.
The pharmacy benefits manager trade group, the Pharmaceutical Care Management Association, also weighed in on the subject, saying Mylan was the latest drugmaker trying to reframe a pricing problem into a coverage problem.
"Blaming payers for these massive price hikes is a red herring and doesn't pass the laugh tests with policymakers," it said in a statement.
— CNBC's Dan Mangan contributed to this report.